N/A N=101 Normal Liver Stiffness by MR Elastography
Liver Diseases
Primary: Liver Stiffness — 2.1 kPa
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=150 Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants With Treatment Success of a 2-Grade IGA Score Improvement From Baseline and an IGA Score of Clear or Almost Clear at Week 2 — 18; 18; 3; 1…
Phase 1 N=23 Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive
HIV Infections
Primary: Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of EE — 748.7 Hour*picograms per…
N/A N=52 Interscalene Brachial Plexus Block Combined With Suprascapular Nerve Block
Rotator Cuff Injury
Primary: Visual Analog Scale (VAS) Pain Score — 2.0; 2.6; 1.7; 2.6 units on a scale
Phase 3 N=340 Prophylactic Ivermectin in COVID-19 Contacts
COVID
Primary: Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath) — 15; 59 Participants
Phase 4 N=58 Minocycline Pharmacokinetics (ACUMIN)
Bacterial Infection
Primary: Calculated Exposure Measures for Area Under the Curve 0 to 24 Hours After a Dose (AUC0-24) — 24.3 mg·hr/L
N/A N=54 Repeated Sweet Breakfasts and Subsequent Sweet Food Preferences and Intakes
Repeated Sweet Food Consumption
Primary: Food Preferences — 73; 68; 54; 50 units on a scale
N/A N=200 Improve Glaucoma Medication Adherence
Glaucoma
Primary: Proportion of Prescribed Glaucoma Medication Doses Taken on Schedule — .84; 0.62 proportion of doses — p=<0.0001
Phase 2 N=117 A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28 — -5.12; -5.94; -5.02; -5.25 mmHg (milimeters of mercury)
Phase 4 N=15 Immunologic Response to Secukinumab in Plaque Psoriasis
Psoriasis
Primary: Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline — -1.42 percent change from week 0
Phase 2 N=18 A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
Prostate Cancer
Primary: Number of Lesions With Gleason Score ≥ 7 Identified by Ultrasound Molecular Imaging — 17; 8 number of lesions
Phase 2 N=176 Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
Primary Open Angle Glaucoma · Ocular Hypertension · Pigmentary Glaucoma
Primary: Change From Baseline Mean Diurnal Intraocular Pressure (IOP) in the Study Eye on Day 28 — -6.96; -7.09; -8.20; -6.02 mmHg (milimeters of mercury)
N/A N=111 Opiate Prescribing Guidelines Following Hip Arthroscopy
Hip Injuries
Primary: Numeric Pain Rating Scale (NPRS) Pain Scores — 4.2; 4.0 score on a scale
N/A N=14 Stereotactic Radiation Therapy for Pediatric Sarcomas
Sarcoma · Metastatic Disease · Bony Sites
Primary: Lesion-specific Local Control at 6 Months Post-SBRT as Assessed by Percentage of Lesions Locally Controlled — 95 percentage of lesions
Phase 3 N=496 Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
HIV-1 Infection
Primary: Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set — 0.6; 1.8 percentage of…